On the other hand, several studies have demonstrated that activation of PPAR-γ2 in hepatocytes is sufficient to initiate hepatic steatosis through mechanisms involving activation of lipogenic genes, de novo lipogenesis, and increased hepatic TG concentrations [19], even independently of SREBP-1c activation [20]. The gene discussed is SREBF1; the disease is Hepatic steatosis.